Frequent nighttime urination, weak urine flow, and a feeling of incomplete emptying are common issues among middle-aged and older men, often linked to benign prostatic hyperplasia (BPH). This age-related condition affects quality of life but is manageable with lifestyle adjustments, medication, or minimally invasive surgery. If you experience persistent urinary discomfort, avoid self-diagnosis. Seek professional urological examination for timely and appropriate care.

Shanghai, July 6, 2026 — Jiahui International Cancer Center (JICC) announced that a 59-year-old male patient from New Zealand has successfully finished T-cell apheresis for Satricabtagene autoleucel (CT041). This marks the first international patient to complete T-cell collection in China for the world’s first approved solid tumor CAR-T therapy, demonstrating China’s global competitiveness in translational cell therapy and showcasing Chinese innovative treatments to global patients.

Independently developed by Sichuan Biokin Pharmaceutical Co., Ltd., Izalontamab Brengitecan for Injection (Iza-Bren) is a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (bispecific ADC). It received its first NMPA approval in June 2026 for adult patients with recurrent/metastatic nasopharyngeal carcinoma who failed at least two lines of systemic chemotherapy plus PD-1/PD-L1 inhibitors, and previously obtained FDA Breakthrough Therapy Designation.